

**ESOP abstract. Practical Symposium – In-house production of CAR-T-therapy.
M^a Estela Moreno, Clinical Pharmacist, Sant Pau Campus Salut Barcelona,
Spain**

The integration of chimeric antigen receptor T-cell (CAR-T) therapy into onco-hematological treatment regimens represents a significant advance in cancer care. In this session, we will explore the in-house production of CAR-T therapy at Sant Pau Campus Salut Barcelona and highlight the central role of clinical oncology pharmacists in this process.

The in-house production of CAR-T cells involves a complex, multidisciplinary effort to produce, modify and reinfuse patient-specific T cells to target malignant cells. Clinical pharmacists play a critical role in this process by ensuring the accuracy and safety of the entire process, validating the chemotherapy, managing potential drug interactions, and monitoring for adverse effects. Their expertise in pharmacokinetics and pharmacodynamics is essential for optimizing dosing regimens and mitigating toxicities. In addition, oncology pharmacists provide essential patient education and support throughout therapy to ensure adherence and address concerns.

Oncology pharmacists work closely with the broader healthcare team, including physicians, nurses, and laboratory professionals, to ensure a cohesive and comprehensive approach to patient care.

Join us to understand the evolving responsibilities of the clinical oncology pharmacist in the era of in-house CAR-T therapy highlighting their contributions to patient safety, therapeutic efficacy, and overall quality of care.